Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-dopamine-transporter-saporin
- Development stage
- Preclinical
- Lead developer
- Advanced Targeting Systems
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intracerebral, Intraparenchymal, Microinjection (research Use In Animals)
01
Overview
**Anti-dopamine-transporter-saporin** is a targeted immunotoxin consisting of a rat monoclonal antibody directed against the extracellular domain of the dopamine transporter (DAT) chemically conjugated to saporin, a ribosome-inactivating protein derived from *Saponaria officinalis*. This reagent is used in research settings to selectively ablate dopaminergic neurons expressing DAT, primarily in animal models of neurological disorders such as Parkinson’s disease. Upon binding to DAT on the cell surface, the antibody-toxin complex is internalized, where saporin inactivates ribosomes, halting protein synthesis and causing cell death. This targeted approach allows for selective lesioning of dopaminergic neuronal populations, thereby enabling specific mechanistic studies of diseases involving dopaminergic systems[1][3][4][5].
- Brand names
- Anti-DAT-SAP
- Other names
- anti-dopamine transporter saporinanti-DAT saporinAnti-Dopamine Transporter-Saporin
02
Targets
DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on anti-dopamine-transporter-saporin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-dopamine-transporter-saporin.